Single Ascending Dose (SAD), Double-Blind, Placebo Controlled Study.~To evaluate the safety and tolerability of single ascending doses of CTI-1601 in subjects with Friedreich's ataxia.~Secondary Objectives:~To evaluate the pharmacokinetics (PK) of CTI-1601 following increasing single doses of subcutaneously (SC) administered CTI-1601.~To evaluate the pharmacodynamics (PD) of CTI-1601 following increasing single doses of SC administered CTI-1601.~CTI-1601 or Placebo - Dose/Mode of Administration: Single Dose/Subcutaneous
To evaluate the safety and tolerability of single ascending doses of CTI-1601 in participants with Friedreich's ataxia